 |
 Video: What is a Stock Split?
|
|
|
| Eledon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis. Co.'s lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand. Tegoprubart is engineered to improve safety and provide pharmacokinetic, pharmacodynamic and dosing advantages. By blocking CD40L and not the CD40 receptor, tegoprubart inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. According to our Eledon Pharmaceuticals stock split history records, Eledon Pharmaceuticals has had 0 splits. | |
|
Eledon Pharmaceuticals (ELDN) has 0 splits in our Eledon Pharmaceuticals stock split history database.
Looking at the Eledon Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Eledon Pharmaceuticals shares, starting with a $10,000 purchase of ELDN, presented on a split-history-adjusted basis factoring in the complete Eledon Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
09/18/2014 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$19.77 |
|
| End price/share: |
$2.06 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-89.58% |
|
| Average Annual Total Return: |
-20.97% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,041.56 |
|
| Years: |
9.61 |
|
|
|
|
|
